abrdn Life Sciences Investors (NYSE:HQL) Sees Significant Growth in Short Interest

abrdn Life Sciences Investors (NYSE:HQL) was the target of a large growth in short interest during the month of March. As of March 31st, there was short interest totaling 39,370 shares, a growth of 22.2% from the March 15th total of 32,205 shares. Based on an average trading volume of 103,796 shares, the days-to-cover ratio is presently 0.4 days. Currently, 0.2% of the shares of the company are short sold.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Uhlmann Price Securities LLC grew its stake in shares of abrdn Life Sciences Investors by 2.3% during the 1st quarter. Uhlmann Price Securities LLC now owns 77,857 shares of the company’s stock valued at $1,267,000 after acquiring an additional 1,719 shares during the period. World Investment Advisors raised its stake in abrdn Life Sciences Investors by 7.2% during the 4th quarter. World Investment Advisors now owns 99,520 shares of the company’s stock worth $1,670,000 after acquiring an additional 6,654 shares during the period. Invesco Ltd. bought a new stake in abrdn Life Sciences Investors during the 4th quarter worth approximately $275,000. Mercer Global Advisors Inc. ADV purchased a new position in abrdn Life Sciences Investors during the fourth quarter valued at approximately $177,000. Finally, Evolve Private Wealth LLC purchased a new position in abrdn Life Sciences Investors during the fourth quarter valued at approximately $199,000. Institutional investors own 32.21% of the company’s stock.

abrdn Life Sciences Investors Trading Up 0.9%

Shares of NYSE:HQL traded up $0.16 during midday trading on Friday, hitting $18.05. The company had a trading volume of 134,715 shares, compared to its average volume of 106,823. abrdn Life Sciences Investors has a 12-month low of $11.72 and a 12-month high of $18.10. The company has a fifty day moving average of $16.76 and a two-hundred day moving average of $16.80.

abrdn Life Sciences Investors Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, March 31st. Shareholders of record on Friday, February 20th were given a $0.56 dividend. The ex-dividend date was Friday, February 20th. This is a positive change from abrdn Life Sciences Investors’s previous quarterly dividend of $0.50. This represents a $2.24 dividend on an annualized basis and a yield of 12.4%.

About abrdn Life Sciences Investors

abrdn Life Sciences Investors (NYSE: HQL) is a closed-end management investment company that seeks capital appreciation through investment in the life sciences sector. Established in 1994, the trust focuses on equity and equity-related securities of companies engaged in biotechnology, pharmaceuticals, medical devices, diagnostics and related fields. Its closed-end structure allows portfolio managers to maintain a stable pool of capital, pursue long-term investment strategies and employ leverage when deemed appropriate.

The fund’s portfolio spans both public and private companies, with an emphasis on businesses driving innovation in drug development, gene therapy, precision medicine and healthcare technology.